REGMF (RemeGen Co) Short-Term Debt : $128.6 Mil (As of Jun. 2024)

View and export this data going back to 2020. Start your Free Trial

What is RemeGen Co Short-Term Debt?

RemeGen Co's Short-Term Debt for the quarter that ended in Jun. 2024 was $128.6 Mil.

RemeGen Co's quarterly Short-Term Debt increased from Jun. 2023 ($1.7 Mil) to Dec. 2023 ($40.1 Mil) and increased from Dec. 2023 ($40.1 Mil) to Jun. 2024 ($128.6 Mil).

RemeGen Co's annual Short-Term Debt stayed the same from Dec. 2021 ($0.0 Mil) to Dec. 2022 ($0.0 Mil) but then increased from Dec. 2022 ($0.0 Mil) to Dec. 2023 ($40.1 Mil).

RemeGen Co Short-Term Debt Historical Data

The historical data trend for RemeGen Co's Short-Term Debt can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

RemeGen Co Short-Term Debt Chart

RemeGen Co Annual Data

Trend

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Dec24

Short-Term Debt

Get a 7-Day Free Trial

16.53

40.10

188.20

RemeGen Co Semi-Annual Data
	Dec18	Jun19	Dec19	Jun20	Dec20	Jun21	Dec21	Jun22	Dec22	Jun23	Dec23	Jun24	Dec24
Short-Term Debt	Get a 7-Day Free Trial								-	1.66	40.10	128.59	188.20

RemeGen Co Short-Term Debt Explanation

Short-Term Debt represents the total amount of Long-Term Debt such as bank loans and commercial paper, which is due within one year.

RemeGen Co Short-Term Debt Related Terms

Thank you for viewing the detailed overview of RemeGen Co's Short-Term Debt provided by GuruFocus.com. Please click on the following links to see related term pages.

RemeGen Co Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » RemeGen Co Ltd (OTCPK:REGMF) » Definitions » Short-Term Debt

Comparable Companies

Traded in Other Exchanges

09995:Hong Kong REG:Germany 688331:China

Address

58 Middle Beijing Road, Yantai Area of Shandong Pilot Free Trade Zone, Yantai Development Zone, Yantai, CHN

Website

https://www.remegen.com

RemeGen Co Ltd is a China-based company mainly engaged in the research, development and manufacture of innovative biopharmaceuticals. The company offers Telitacicept (RC18) for use in the treatment of systemic lupus erythematosus an autoimmune disease and Disitamab Vedotin (RC48) for use in the treatment of various cancers. The company's products are mainly used to treat major diseases such as autoimmune diseases, oncology, and ophthalmology. The company has its operations in China and the USA and derives the majority of its revenue from China.